Suppr超能文献

体外实验研究经乳房内给予第一代头孢菌素后牛粪便中产超广谱β-内酰胺酶大肠杆菌的选择潜力。

Potential of ESBL-producing Escherichia coli selection in bovine feces after intramammary administration of first generation cephalosporins using in vitro experiments.

机构信息

Division Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

University Farm Animal Clinic, Harmelen, The Netherlands.

出版信息

Sci Rep. 2022 Sep 5;12(1):15083. doi: 10.1038/s41598-022-15558-z.

Abstract

Selection and spread of Extended Spectrum Beta-Lactamase (ESBL) -producing Enterobacteriaceae within animal production systems and potential spillover to humans is a major concern. Intramammary treatment of dairy cows with first-generation cephalosporins is a common practice and potentially selects for ESBL-producing Enterobacteriaceae, although it is unknown whether this really occurs in the bovine fecal environment. We aimed to study the potential effects of intramammary application of cephapirin (CP) and cefalonium (CL) to select for ESBL-producing Escherichia coli in the intestinal content of treated dairy cows and in manure slurry, using in vitro competition experiments with ESBL and non-ESBL E. coli isolates. No selection of ESBL-producing E. coli was observed at or below concentrations of 0.8 µg/ml and 4.0 µg/ml in bovine feces for CP and CL, respectively, and at or below 8.0 µg/ml and 4.0 µg/ml, respectively, in manure slurry. We calculated that the maximum concentration of CP and CL after intramammary treatment with commercial products will not exceed 0.29 µg/ml in feces and 0.03 µg/ml in manure slurry. Therefore, the results of this study did not find evidence supporting the selection of ESBL-producing E. coli in bovine feces or in manure slurry after intramammary use of commercial CP or CL-containing products.

摘要

在动物生产系统中,产Extended Spectrum Beta-Lactamase(ESBL)的肠杆菌科的选择和传播,以及对人类的潜在溢出,是一个主要关注点。在奶牛的乳腺内用第一代头孢菌素治疗是一种常见的做法,可能会选择产 ESBL 的肠杆菌科,但尚不清楚这种情况是否真的会在牛的粪便环境中发生。我们的目的是研究在乳腺内应用头孢匹林(CP)和头孢罗宁(CL)是否会在接受治疗的奶牛的肠道内容物和粪浆中选择产 ESBL 的大肠杆菌,使用 ESBL 和非 ESBL 大肠杆菌分离株的体外竞争实验。在牛粪便中,CP 和 CL 的浓度分别为 0.8 µg/ml 和 4.0 µg/ml 及以下,以及在粪浆中分别为 8.0 µg/ml 和 4.0 µg/ml 及以下时,没有观察到产 ESBL 的大肠杆菌的选择。我们计算出,在使用商业产品进行乳腺内治疗后,CP 和 CL 的最大浓度在粪便中不会超过 0.29 µg/ml,在粪浆中不会超过 0.03 µg/ml。因此,本研究的结果没有发现证据支持在乳腺内使用含有 CP 或 CL 的商业产品后,在牛粪便或粪浆中选择产 ESBL 的大肠杆菌。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f69/9445091/62dec004b300/41598_2022_15558_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验